Base de dados : MEDLINE
Pesquisa : B04.280.375.650.425 [Categoria DeCS]
Referências encontradas : 23403 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2341 ir para página                         

  1 / 23403 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464845
[Au] Autor:Wei X; Li N; Li S; Shi J; Guo W; Zheng Y; Cheng S
[Ad] Endereço:Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Yangpu District, Shanghai, 200438, China.
[Ti] Título:Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma.
[So] Source:BMC Cancer;17(1):304, 2017 May 02.
[Is] ISSN:1471-2407
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vascular invasion, including microvascular invasion (MVI) and portal vein tumor thrombus (PVTT), is associated with the postoperative recurrence of hepatocellular carcinoma (HCC). We aimed to investigate the potential impact of hepatitis B virus (HBV) activity on the development of vascular invasion. METHODS: Patients with HBV and tumor-related factors of HCC who had undergone hepatectomy were retrospectively enrolled and analyzed to identify the risk factors for developing vascular invasion. RESULTS: A total of 486 patients were included in this study. The overall proportion of patients with vascular invasion, including MVI and PVTT, was 60.3% (293/486). The incidence of MVI was 58.2% (283/486) whereas PVTT was 22.2% (108/486). Univariate analysis revealed that positive Hepatitis B virus surface Antigen (HBsAg) was significantly associated with the presence of vascular invasion. In a multivariate regression analysis carried out in patients with HBV-related HCC, positive Hepatitis B virus e Antigen (HBeAg)(OR = 1.83, P = 0.019) and a detectable seral HBV DNA load (OR = 1.68, P = 0.027) were independent risk factors of vascular invasion. The patients in the severe MVI group had a significantly higher rate of positive seral HBsAg (P = 0.005), positive seral HBeAg (P = 0.016), a detectable seral HBV DNA load (> 50 IU/ml) (P < 0.001) and a lower rate of anti-viral treatment (P = 0.002) compared with those in the mild MVI group and MVI-negative group. Whereas, HCC with PVTT invading the main trunk showed a significantly higher rate of positive HBsAg (P = 0.007), positive HBeAg (P = 0.04), cirrhosis (P = 0.005) and a lower rate of receiving antiviral treatment (P = 0.009) compared with patients with no PVTT or PVTT invading the ipsilateral portal vein. Patients with vascular invasion also had a significantly higher level of seral HBV DNA load than patients without vascular invasion (P = 0.008). CONCLUSIONS: In HCC patients, HBV infection and active HBV replication were associated with the development of vascular invasion.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular
Vírus da Hepatite B
Hepatite B
Neoplasias Hepáticas
Neovascularização Patológica
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antivirais/uso terapêutico
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Replicação Viral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12885-017-3293-6


  2 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460481
[Au] Autor:Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J
[Ad] Endereço:Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
[Ti] Título:SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
[So] Source:Oncotarget;8(16):27263-27276, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The non-receptor tyrosine phosphatase SHP2 has scaffolding functions in signal transduction cascades downstream of growth receptors. A recent study suggested that SHP2 acts as a tumor suppressor during hepatocellular carcinoma (HCC) development. Herein we examined whether SHP2 links the HBx-NF-κB pathway to EGFR signaling during HCC development. The overexpression of HBx or NF-κB led to increased SHP2 expression via NF-κB binding to the Shp2 promoter. EGF treatment induced ERK activation as well as the rapid assembly of SHP2, EGFR, and Gab1. Upon LPS stimulation, NF-κB-SHP2-ERK activation and phosphorylated STAT3 levels exhibited a negative correlation in vitro. By contrast, in patients with HBV-associated HCC, NF-κB-SHP2-ERK and IL-6-JAK-STAT3 pathway activity levels were concomitantly higher in adjacent non-neoplastic tissues than in HCC tissues. The immunohistochemical analysis of 162 tissues of patients with HCC revealed that SHP2 levels were significantly higher in non-neoplastic background tissues than in corresponding HCC tissues and considerably increased in background liver tissues with advanced fibrosis (P < 0.001). SHP2 expression increased gradually from normal liver to chronic hepatitis, cirrhosis, and background liver with a dysplastic nodule, but was decreased or lost in dysplastic nodules and HCC. This is the first report to describe the existence of the HBx-NF-κB-SHP2 pathway, linking HBV infection to the EGFR-RAS-RAF-MAPK pathway in the liver. SHP2 depletion from the negative crosstalk between NF-κB and STAT3 accelerates HCC development.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/etiologia
Carcinoma Hepatocelular/metabolismo
Neoplasias Hepáticas/etiologia
Neoplasias Hepáticas/metabolismo
NF-kappa B/metabolismo
Proteína Tirosina Fosfatase não Receptora Tipo 11/genética
Transativadores/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Carcinoma Hepatocelular/patologia
Carcinoma Hepatocelular/cirurgia
Linhagem Celular Tumoral
Feminino
Fibrose
Regulação Neoplásica da Expressão Gênica
Vírus da Hepatite B/fisiologia
Seres Humanos
Cirrose Hepática/etiologia
Cirrose Hepática/metabolismo
Cirrose Hepática/patologia
Neoplasias Hepáticas/patologia
Neoplasias Hepáticas/cirurgia
Masculino
Meia-Idade
Modelos Biológicos
Gradação de Tumores
Estadiamento de Neoplasias
Regiões Promotoras Genéticas
Ligação Proteica
Proteína Tirosina Fosfatase não Receptora Tipo 11/metabolismo
Fator de Transcrição STAT3/metabolismo
Transdução de Sinais
Proteínas ras/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (NF-kappa B); 0 (STAT3 Transcription Factor); 0 (Trans-Activators); 0 (hepatitis B virus X protein); EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 11); EC 3.6.5.2 (ras Proteins)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15930


  3 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27774620
[Au] Autor:Vendramin C; McGuckin S; Alwan F; Westwood JP; Thomas M; Scully M
[Ad] Endereço:Department of Haematology, University College London Hospital.
[Ti] Título:A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.
[So] Source:Transfusion;57(1):131-136, 2017 01.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients presenting with acute episodes of thrombotic microangiopathies (TMAs) require urgent access to plasma exchange (PEX). OctaplasLG, a solvent/detergent fresh-frozen plasma product that has undergone viral inactivation and prion reduction step, has been used in our institution since 2013, replacing Octaplas. STUDY DESIGN AND METHODS: We prospectively reviewed 981 PEX procedures where OctaplasLG was the replacement fluid in 90 patients admitted acutely with a TMA presentation within our institution from January 1, 2013, to December 31, 2015. We recorded citrate toxicities, plasma reactions, viral transfer, complications related to central venous catheter, and venous thrombotic events (VTEs). RESULTS: Citrate toxicities were 5.4%, plasma reactions were 2%, and all were classified as Grade 1 or 2. VTE had an incidence of 12.2%, although 50% of the episodes occurred in early remission when patients were not receiving PEX. No line insertions complications were recorded. Line-associated infections were 2.2%. Hepatitis B and C serology and human immunodeficiency virus (HIV) were checked on admission. There were four patients who may have had passive transient transfer of hepatitis B antibodies from pooled plasma. No hepatitis C or HIV viral transfer was documented after treatment and no seroconversion was detected after treatment. CONCLUSION: Our data have demonstrated that the incidence of complications during PEX is low and using OctaplasLG is comparable to the low incidence of reactions. No cases of anaphylaxis, transfusion-related acute lung injury, or fatal plasma reactions were seen. There was no evidence of viral transmission or seroconversion after treatment.
[Mh] Termos MeSH primário: Desinfecção/métodos
Troca Plasmática/métodos
Plasma
Príons
Microangiopatias Trombóticas/terapia
Inativação de Vírus
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Detergentes/química
Feminino
HIV
Infecções por HIV/prevenção & controle
Hepacivirus
Hepatite B/prevenção & controle
Vírus da Hepatite B
Hepatite C/prevenção & controle
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Solventes/química
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Detergents); 0 (Prions); 0 (Solvents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1111/trf.13877


  4 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28741237
[Au] Autor:Zhand S; Tabarraei A; Nazari A; Moradi A
[Ad] Endereço:Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
[Ti] Título:Cytotoxic T lymphocytes and CD4 epitope mutations in the pre-core/core region of hepatitis B virus in chronic hepatitis B carriers in Northeast Iran.
[So] Source:Indian J Gastroenterol;36(4):253-257, 2017 Jul.
[Is] ISSN:0975-0711
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:BACKGROUNDS: Hepatitis B virus (HBV) is vulnerable to many various mutations. Those within epitopes recognized by sensitized T cells may influence the re-emergence of the virus. This study was designed to investigate the mutation in immune epitope regions of HBV pre-core/core among chronic HBV patients of Golestan province, Northeast Iran. METHODS: In 120 chronic HBV carriers, HBV DNA was extracted from blood plasma samples and PCR was done using specific primers. Direct sequencing and alignment of the pre-core/core region were applied using reference sequence from Gene Bank database (Accession Number AB033559). RESULTS: The study showed 27 inferred amino acid substitutions, 9 of which (33.3%) were in CD4 and 2 (7.4%) in cytotoxic T lymphocytes' (CTL) epitopes and 16 other mutations (59.2%) were observed in other regions. CONCLUSIONS: CTL escape mutations were not commonly observed in pre-core/core sequences of chronic HBV carriers in the locale of study. It can be concluded that most of the inferred amino acid substitutions occur in different immune epitopes other than CTL and CD4.
[Mh] Termos MeSH primário: Antígenos CD4/genética
Portador Sadio/virologia
Epitopos/genética
Vírus da Hepatite B/genética
Vírus da Hepatite B/imunologia
Hepatite B Crônica/virologia
Mutação Puntual
Linfócitos T Citotóxicos/imunologia
[Mh] Termos MeSH secundário: Substituição de Aminoácidos
Portador Sadio/imunologia
Epitopos/química
Epitopos/imunologia
Hepatite B Crônica/imunologia
Seres Humanos
Irã (Geográfico)
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD4 Antigens); 0 (Epitopes)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1007/s12664-017-0767-z


  5 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775391
[Au] Autor:Duan X; Yuan S; Wang K
[Ad] Endereço:School of Management, University of Shanghai for Science and Technology, Shanghai 200093, China. email: xcduan82@126.com.
[Ti] Título:Dynamics of a diffusive age-structured HBV model with saturating incidence.
[So] Source:Math Biosci Eng;13(5):935-968, 2016 10 01.
[Is] ISSN:1551-0018
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this paper, we propose and investigate an age-structured hepatitis B virus (HBV) model with saturating incidence and spatial diffusion where the viral contamination process is described by the age-since-infection. We first analyze the well-posedness of the initial-boundary values problem of the model in the bounded domain Ω âŠ‚ Rn and obtain an explicit formula for the basic reproductive number R0 of the model. Then we investigate the global behavior of the model in terms of R0: if R0 ≤ 1, then the uninfected steady state is globally asymptotically stable, whereas if R0 > 1, then the infected steady state is globally asymptotically stable. In addition, when R0> 1, by constructing a suitable Lyapunov-like functional decreasing along the travelling waves to show their convergence towards two steady states as t tends to ∞, we prove the existence of traveling wave solutions. Numerical simulations are provided to illustrate the theoretical results.
[Mh] Termos MeSH primário: Hepatite B/epidemiologia
Modelos Biológicos
[Mh] Termos MeSH secundário: Distribuição por Idade
Simulação por Computador
Vírus da Hepatite B
Seres Humanos
Incidência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.3934/mbe.2016024


  6 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775386
[Au] Autor:Manyombe ML; Mbang J; Lubuma J; Tsanou B
[Ad] Endereço:Department of Mathematics, Faculty of Science, University of Yaounde 1, P.O. Box 812 Yaounde, Cameroon. email: luthermann.3ml@gmail.com.
[Ti] Título:Global dynamics of a vaccination model for infectious diseases with asymptomatic carriers.
[So] Source:Math Biosci Eng;13(4):813-840, 2016 08 01.
[Is] ISSN:1551-0018
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this paper, an epidemic model is investigated for infectious diseases that can be transmitted through both the infectious individuals and the asymptomatic carriers (i.e., infected individuals who are contagious but do not show any disease symptoms). We propose a dose-structured vaccination model with multiple transmission pathways. Based on the range of the explicitly computed basic reproduction number, we prove the global stability of the disease-free when this threshold number is less or equal to the unity. Moreover, whenever it is greater than one, the existence of the unique endemic equilibrium is shown and its global stability is established for the case where the changes of displaying the disease symptoms are independent of the vulnerable classes. Further, the model is shown to exhibit a transcritical bifurcation with the unit basic reproduction number being the bifurcation parameter. The impacts of the asymptomatic carriers and the effectiveness of vaccination on the disease transmission are discussed through through the local and the global sensitivity analyses of the basic reproduction number. Finally, a case study of hepatitis B virus disease (HBV) is considered, with the numerical simulations presented to support the analytical results. They further suggest that, in high HBV prevalence countries, the combination of effective vaccination (i.e. ≥ 3 doses of HepB vaccine), the diagnosis of asymptomatic carriers and the treatment of symptomatic carriers may have a much greater positive impact on the disease control.
[Mh] Termos MeSH primário: Doenças Assintomáticas/epidemiologia
Doenças Transmissíveis/epidemiologia
Epidemias/estatística & dados numéricos
Modelos Teóricos
Vacinação/estatística & dados numéricos
[Mh] Termos MeSH secundário: Número Básico de Reprodução
Epidemias/prevenção & controle
Vírus da Hepatite B/fisiologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.3934/mbe.2016019


  7 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453967
[Au] Autor:Kosinska AD; Bauer T; Protzer U
[Ad] Endereço:Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany; German Center for Infection research (DZIF), Munich Partner Site, Germany.
[Ti] Título:Therapeutic vaccination for chronic hepatitis B.
[So] Source:Curr Opin Virol;23:75-81, 2017 04.
[Is] ISSN:1879-6265
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A therapeutic vaccine is meant to activate the patient's immune system to fight and finally control or ideally eliminate an already established infectious pathogen. Whereas the success of prophylactic vaccination is based on rapid antibody-mediated neutralization of an invading pathogen, control and elimination of persistent viruses such as hepatitis, herpes or papilloma viruses requires multi-specific and polyfunctional effector T cell responses. These are ideally directed against continuously expressed viral antigens to keep the pathogen in check. Activation of a humoral immune response in order to lower viral antigen load and to limit virus spread, however, confers an additional benefit. Therapeutic vaccines are under development for a number of chronic infections and require an intelligent vaccine design. Hepatitis B virus (HBV) infection may serve as a prime example since a spontaneous, immune-mediated recovery of chronic hepatitis B and an elimination of the virus is possible even if it is observed only in very rare cases. In this review, we summarize the current knowledge and potential improvements of therapeutic vaccines for chronic hepatitis B.
[Mh] Termos MeSH primário: Vacinas contra Hepatite B/uso terapêutico
Vírus da Hepatite B/imunologia
Hepatite B Crônica/terapia
Imunoterapia/métodos
[Mh] Termos MeSH secundário: Descoberta de Drogas/tendências
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hepatitis B Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  8 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29288943
[Au] Autor:Qiu J; Gong Q; Gao J; Chen W; Zhang Y; Gu X; Tang D
[Ad] Endereço:Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China; Department of Pharmaceutical Analysis, School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China.
[Ti] Título:Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
[So] Source:Eur J Med Chem;144:424-434, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:As an ongoing search for potent non-nucleoside anti-HBV agents with novel structures, we described a series of phenyl propionamide derivatives (3a-b, 4a-e, 7a-g, 8a-h and 9a-b) by pharmacophore fusion strategy in the present work. All the compounds exhibited an anti-HBV activity to some extent. Among them, compounds 8d and 9b displayed most potent anti-HBV activity with IC values on HBV DNA replication of 0.46 and 0.14 µM, respectively. And the selective index values of 8d and 9b were more than 217.39 and 153.14, suggesting that 8d and 9b exhibited favorable safety profiles. Interestingly, 8d and 9b possessed significantly antiviral activities against lamivudine and entecavir resistant HBV mutants with IC values of 0.77 and 0.32 µM. Notably, preliminary anti-HBV action mechanism studies showed that 8d could inhibit intracellular HBV pgRNA and RT activity of the HBV polymerase. Molecular docking studies suggested that compound 8d could fit into the dimer-dimer interface of HBV core protein by hydrophobic interaction. In addition, in silico prediction of physicochemical properties showed that 8d conformed well to the Lipinski's rule of five, suggesting its potential for use as a drug like molecule. Taken together, 8d possessed significantly anti-HBV activity, low toxicity, diverse anti-HBV mechanism and favorable physicochemical properties, and warranted further investigation as a promising non-nucleoside anti-HBV candidate.
[Mh] Termos MeSH primário: Amidas/farmacologia
Antivirais/farmacologia
Desenho de Drogas
Vírus da Hepatite B/efeitos dos fármacos
[Mh] Termos MeSH secundário: Amidas/síntese química
Amidas/química
Antivirais/síntese química
Antivirais/química
Sobrevivência Celular/efeitos dos fármacos
Replicação do DNA/efeitos dos fármacos
Relação Dose-Resposta a Droga
Células Hep G2
Seres Humanos
Testes de Sensibilidade Microbiana
Simulação de Acoplamento Molecular
Estrutura Molecular
Relação Estrutura-Atividade
Replicação Viral/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amides); 0 (Antiviral Agents); QK07G0HP47 (propionamide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171231
[St] Status:MEDLINE


  9 / 23403 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29366781
[Au] Autor:Cheng ST; Ren JH; Cai XF; Jiang H; Chen J
[Ad] Endereço:Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China.
[Ti] Título:HBx-elevated SIRT2 promotes HBV replication and hepatocarcinogenesis.
[So] Source:Biochem Biophys Res Commun;496(3):904-910, 2018 02 12.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sirtuin 2 (SIRT2) is a class III histone deacetylase that has been implicated to promote HCC development. However, the functional role of SIRT2 in HBV is still unclear. In this study, we found that HBV could upregulate SIRT2 expression. Additionally, HBx could activate SIRT2 promoter to upregulate the mRNA and protein level of SIRT2. Furthermore, we found that SIRT2 could facilitate HBV transcription and replication. Finally, we demonstrated that upregulation of SIRT2 by HBx promoted hepatocarcinogenesis. In summary, our findings revealed a novel function of SIRT2 in HBV and HBV-mediated HCC. First, SIRT2 could promote HBV replication. And then HBx-elevated SIRT2 could enhance the transformation of HBV-mediated HCC. Those findings highlight the potential role of SIRT2 in HBV and HBV-mediated HCC by interaction with HBx.
[Mh] Termos MeSH primário: Proteínas Adaptadoras de Transdução de Sinal/metabolismo
Carcinogênese/metabolismo
Vírus da Hepatite B/fisiologia
Neoplasias Hepáticas/metabolismo
Neoplasias Hepáticas/virologia
Sirtuína 2/metabolismo
Replicação Viral/fisiologia
[Mh] Termos MeSH secundário: Carcinogênese/patologia
Linhagem Celular Tumoral
Hepatite B/metabolismo
Hepatite B/virologia
Seres Humanos
Neoplasias Hepáticas/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adaptor Proteins, Signal Transducing); 0 (HBXIP protein, human); EC 3.5.1.- (SIRT2 protein, human); EC 3.5.1.- (Sirtuin 2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  10 / 23403 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320552
[Au] Autor:Carimo AA; Gudo ES; Maueia C; Mabunda N; Chambal L; Vubil A; Flora A; Antunes F; Bhatt N
[Ad] Endereço:Internal Medicine Department, Maputo Central Hospital, Maputo, Mozambique.
[Ti] Título:First report of occult hepatitis B infection among ART naïve HIV seropositive individuals in Maputo, Mozambique.
[So] Source:PLoS One;13(1):e0190775, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The prevalence of hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection in Mozambique is one of the highest in the world, though in spite of this the prevalence of occult hepatitis B infection (OBI) is unknown. OBJECTIVES: This study was conducted with the aim to investigate the prevalence of OBI and frequency of isolated hepatitis B core antibody (anti-HBc alone) among antiretroviral (ART) naïve HIV-positive patients in Mozambique. METHODS: A cross-sectional study was conducted in two health facilities within Maputo city. All ART-naive HIV seropositive patients attending outpatient clinics between June and October 2012 were consecutively enrolled. Blood samples were drawn from each participant and used for serological measurement of HBV surface antigen (HBsAg), antibodies against HBV surface antigen (anti-HBs) and antibodies against core antigen (anti-HBc) using ELISA. Quantification of HBV DNA was performed by real time PCR. A questionnaire was used to obtain demographics and clinical data. RESULTS: Of the 518 ART-naive HIV-positive subjects enrolled in the study, 90.9% (471/518) were HBsAg negative. Among HBsAg negative, 45.2% (213/471) had isolated anti-HBc antibodies, and the frequency of OBI among patients with anti-HBc alone was 8.3% (17/206). OBI was not correlated either with CD4+ T cells count or transaminases levels. A total of 11.8% of patients with OBI presented elevated HBV DNA level. Frequency of individuals with APRI score > 2 and FIB-4 score > 3.25 was higher in patients with OBI as compared not exposed, immune and anti-HBc alone patients. CONCLUSION: Our data demonstrate for the first time that OBI is prevalent among HIV patients in Mozambique, and will be missed using the commonly available serological assays that measures HBsAg.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico
Infecções por HIV/complicações
Hepatite B/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
DNA Viral/genética
Feminino
Hepatite B/complicações
Vírus da Hepatite B/genética
Vírus da Hepatite B/isolamento & purificação
Seres Humanos
Masculino
Moçambique
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (DNA, Viral)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190775



página 1 de 2341 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde